Preventing transplant rejection requires a combination of careful donor-recipient matching before surgery, powerful medications that suppress the immune system afterward, and consistent long-term monitoring. Modern immunosuppressive regimens have pushed five-year kidney graft survival to 90% for younger recipients of living-donor organs, but rejection remains a real threat at every stage. Here’s what actually happens in your body after a transplant and what’s done to keep your new organ safe.
Why Your Body Attacks a Transplanted Organ
Your immune system is designed to recognize anything that isn’t “you” and destroy it. A transplanted organ carries proteins on its cell surfaces that differ from your own, and your T cells detect those differences almost immediately. Once activated, these T cells multiply rapidly, migrate into the new organ, and begin attacking its tissue directly. They also recruit B cells to produce antibodies against the organ, adding a second line of assault.
This immune response can show up at different speeds. Hyperacute rejection happens within minutes to hours when pre-existing antibodies in your blood immediately attack the donor organ. Acute rejection typically develops in the first weeks to months, driven by T cells infiltrating the graft. Chronic rejection is slower and more insidious, unfolding over months or years as ongoing low-level immune activity gradually scars and stiffens the organ’s blood vessels and tissue. Each type requires a different prevention strategy.
Matching Donor and Recipient Before Surgery
The first line of defense happens before an organ is ever transplanted. Transplant teams type the donor’s and recipient’s human leukocyte antigens (HLA), a set of proteins on cell surfaces that the immune system uses to distinguish self from non-self. The closer the HLA match, the less aggressively your immune system will react. DNA-based typing has largely replaced older blood-based methods and can now identify these proteins at very fine resolution.
Crossmatch testing is equally critical. A sample of your blood is mixed with donor cells in the lab to see whether your antibodies react against them. If your antibodies kill the donor’s T cells in this test, transplantation is considered an absolute contraindication because of the near-certainty of hyperacute rejection. A weaker positive result, where antibodies bind to donor B cells but don’t kill T cells, raises the risk but doesn’t necessarily rule out transplant. In those cases, desensitization treatment before surgery can sometimes reduce antibody levels enough to proceed safely.
Induction Therapy: The First Days After Transplant
Immediately after surgery, most transplant recipients receive a short course of potent biological agents designed to knock back the immune response during the period of highest risk. About 60% of kidney transplant recipients in the United States receive a T cell-depleting agent derived from rabbit antibodies (commonly called rATG), which destroys large numbers of T cells outright. The alternative is a non-depleting antibody that blocks a specific receptor T cells need to multiply.
The choice depends largely on your immunological risk. For patients at high risk of rejection, such as those with pre-formed antibodies or a poor HLA match, the T cell-depleting approach cuts rejection rates nearly in half compared to the non-depleting option. In one study, rejection at five years was 15% with the depleting agent versus 27% without it. For standard-risk patients on modern maintenance drugs, the difference between the two approaches is much smaller, and some evidence suggests the less aggressive option works nearly as well.
Long-Term Maintenance Medications
Once the initial high-risk window passes, you transition to a daily medication regimen you’ll take for the life of the organ. The backbone of modern maintenance therapy is a two- or three-drug combination that targets different steps in the T cell activation process.
Calcineurin inhibitors, most commonly tacrolimus, block an early signal that T cells need to activate and multiply. This drug class has been the cornerstone of transplant immunosuppression for decades. It’s paired with an antimetabolite, usually mycophenolate, which disrupts the DNA copying process that immune cells depend on to reproduce. A meta-analysis of 19 studies found that mycophenolate combined with a calcineurin inhibitor reduced acute rejection risk by 38% compared to the older antimetabolite azathioprine. Many centers add a low-dose corticosteroid as a third agent to broadly dampen inflammatory signaling.
A second class of drugs called mTOR inhibitors (everolimus and sirolimus) blocks a later step in T cell multiplication. These are sometimes used in place of or alongside calcineurin inhibitors, particularly when kidney toxicity from calcineurin inhibitors becomes a concern. In the ZEUS trial, patients who switched from a calcineurin inhibitor to everolimus at about four and a half months after transplant were able to preserve kidney function while maintaining immunosuppression. A newer option, belatacept, works by a completely different mechanism: it prevents T cells from receiving a critical “co-stimulation” signal they need to fully activate.
Side Effects of Lifelong Immunosuppression
Suppressing your immune system effectively enough to protect a transplant comes with real trade-offs. Calcineurin inhibitors are the biggest concern for long-term kidney damage. One study found that nearly 20% of liver transplant recipients developed chronic kidney failure within five years, driven primarily by these drugs. They also contribute to high blood sugar, high cholesterol, and high blood pressure, a cluster of metabolic problems that increases cardiovascular risk over time. Up to 40% of liver transplant recipients develop diabetes after transplant, caused by both calcineurin inhibitors (which impair insulin release) and corticosteroids (which increase insulin resistance).
Corticosteroids carry their own well-known list of complications with prolonged use: weight gain, bone thinning, increased infection risk, changes in facial appearance, and mood disturbances. The overall incidence of cancer after solid organ transplantation is also elevated. One analysis of all U.S. solid organ transplant recipients found a 4.46% rate of post-transplant malignancy in liver recipients, with gastrointestinal cancers being the most common type. A particular concern is post-transplant lymphoproliferative disorder, a group of lymph-tissue cancers closely linked to immunosuppression.
These risks are why transplant teams constantly balance the dose: enough medication to prevent rejection, but as little as possible to limit long-term harm.
Recognizing Early Signs of Rejection
Rejection doesn’t always announce itself with obvious symptoms, which is why routine monitoring matters so much. When symptoms do appear, they tend to be organ-specific. Kidney transplant recipients may notice decreased urine output. Heart recipients may feel increasing shortness of breath or reduced exercise tolerance. Liver recipients might develop yellowing skin or bruise easily. Pancreas recipients may see their blood sugar climb.
More general warning signs include fever, flu-like symptoms (chills, body aches, nausea), a general feeling of being unwell, and occasionally pain or swelling near the transplant site. But many rejection episodes are subclinical, meaning they cause damage without any noticeable symptoms. That’s why transplant centers perform routine biopsies, taking a small tissue sample from the organ at scheduled intervals to look for microscopic evidence of immune attack before it becomes clinically apparent.
Blood tests tracking organ function (kidney or liver values, for instance) are a standard part of follow-up visits. A newer monitoring tool measures donor-derived cell-free DNA circulating in your blood. When the transplanted organ is under immune attack, its cells break down and release fragments of the donor’s DNA into your bloodstream. A rising level of this DNA can signal rejection earlier than traditional lab tests, potentially allowing treatment to start sooner. A recent randomized trial found that using this blood test to guide biopsy timing in high-risk kidney recipients reduced the time to diagnosing antibody-mediated rejection.
Why Taking Medications Consistently Matters
Non-adherence to immunosuppressive medications is one of the leading preventable causes of late graft loss. Yet sticking to the regimen is harder than it sounds. Transplant patients in one qualitative study identified four major barriers: difficulty obtaining specialty medications (which aren’t stocked at every pharmacy and sometimes require mail-order from specialty pharmacies), insurance complications and cost, disruptions to daily routines that lead to missed doses, and side effects like diarrhea, nausea, nerve pain, and brain fog that make people want to skip pills.
Even small disruptions can throw off a medication schedule. Patients who need periodic blood draws to check drug levels are often told to skip their morning dose beforehand, and that single change to their routine can cascade into a missed dose later in the day. Rural patients sometimes have to travel long distances to pharmacies that stock their medications, and getting extra supply for travel requires advance coordination with their transplant team.
Transplant centers that have the most success with adherence use a multidisciplinary approach: clinical pharmacists who help simplify regimens and reduce pill burden, electronic reminders or phone apps for dosing, mental health support for the anxiety and depression that commonly follow transplant, and peer support programs that connect patients with others going through the same experience. If side effects from one medication are driving non-adherence, switching to an alternative within the same drug class (for example, from mycophenolate to azathioprine at an adjusted dose) can sometimes make the regimen tolerable enough to maintain consistently.
What Graft Survival Looks Like Today
Current data from the U.S. national transplant registry shows that five-year kidney graft survival for living-donor transplants reaches 90% in adults aged 18 to 34 and 80.2% in recipients 65 and older. For deceased-donor kidneys, those numbers are 82.2% and 66.1%, respectively. Pediatric outcomes are strong as well: one-year graft failure after deceased-donor kidney transplant in children was just 4% for transplants performed in 2022.
The gap between living-donor and deceased-donor outcomes reflects several factors, including better HLA matching with living donors, shorter time the organ spends without blood flow, and the ability to optimize the recipient’s health before a planned surgery rather than responding to a last-minute organ offer. These numbers have improved steadily over the past two decades, driven largely by better immunosuppressive protocols and more sophisticated matching techniques.